Tracking Cathie Wood: ARK Invest significantly boosted its stake in urban air mobility leader ACHR by over 940,000 shares and trimmed Robinhood to rebalance portfolio allocations

On Wednesday, July 22, 2026, all three major U.S. stock indices closed lower. The S&P 500 fell 0.14% to close at 7,498.96 points. The Nasdaq Composite saw a relatively steeper decline, dropping 0.57% to 25,690.90 points, while the Dow Jones Industrial Average was nearly flat, slipping just 0.01% to close at 52,218.58 points. Overall market sentiment remained cautious, with the technology sector under pressure, acting as the primary drag on the broader market.

Against this backdrop, Cathie Wood’s ARK Invest has taken aggressive counter-cyclical action, doubling down on multiple disruptive innovation sectors amid broader market weakness, while simultaneously rebalancing positions in select financial and healthcare holdings. The overall strategy clearly reflects a 'balanced offense and defense, shedding weaker assets while retaining stronger ones' approach.

Buy-side focus: Comprehensive positioning across air mobility, gene editing, the space economy, and autonomous driving

The most notable move was undoubtedly a significant increase in holdings of$Archer Aviation (ACHR.US)$, with a single-day purchase of as many as 940,434 shares—the largest buy transaction on that day's list. ACHR is a core urban air mobility (UAM) holding that ARK has long bet on. With the eVTOL sector recently gaining momentum from regulatory progress and commercial orders, ARK’s substantial new position likely reflects strong confidence in Archer approaching a critical commercialization milestone.

In the gene editing space, ARK added to its stake in$Prime Medicine (PRME.US)$ by 206,310 shares. Prime Medicine focuses on its proprietary 'prime editing' technology platform, considered one of the foundational approaches for next-generation precision gene therapy. This move likely signals ARK’s optimism about the company’s long-term potential in genetic disease therapeutics, aligning closely with ARK’s established precision medicine investment framework.

In the space economy segment, ARK bought$SpaceX (SPCX.US)$ 121,384 shares. SpaceX represents ARK’s cornerstone investment in private space exploration, and the recent commercial expansion of Starlink alongside continued breakthroughs in heavy-lift rocket technology may have been key factors behind this increased position.

In the blockchain financial infrastructure space, ARK increased its holding in$Securitize (SECZ.US)$ by 66,127 shares. Securitize is a leading platform for real-world asset (RWA) tokenization, and as institutional capital continues flowing into on-chain financial ecosystems, ARK’s move likely reflects its ongoing conviction in the long-term valuation upside of the RWA sector.

ARK also took action in the autonomous driving sector, buying shares of$Pony AI (PONY.US)$ 57,164 shares and$WeRide (WRD.US)$ 49,436 shares, simultaneously increasing its stakes in two leading Chinese autonomous driving companies. This suggests ARK may be intensifying its positioning to track the commercialization progress of Level 4 autonomous driving, aiming to secure an early advantage as the Robotaxi market landscape becomes increasingly clear.

Finally, ARK increased its stake in$COMPASS Pathways (CMPS.US)$ by 42,091 shares. Compass is a representative name in mental health, focusing on innovative depression therapies based on psilocybin (a psychedelic compound). Recent regulatory conditions for psychiatric drugs may be experiencing marginal improvement, and ARK’s additional investment likely reflects its positive outlook on the commercial prospects of such novel therapies.

On the sell side: Adjusting financial and healthcare positions to optimize portfolio structure

The largest-selling position was$Robinhood (HOOD.US)$, with a reduction of 97,325 shares. Robinhood’s share price has recently been volatile due to market sentiment, and ARK’s sale may represent a portfolio rebalancing move—reallocating capital from traditional retail brokerage operations toward holdings more aligned with its core 'disruptive innovation' theme.

In the satellite communications space, ARK reduced its stake in$Iridium Communications (IRDM.US)$ by 40,062 shares. Iridium has served as a relatively defensive holding in ARK’s portfolio; this reduction may indicate that ARK is narrowing its exposure to satellite communications and redirecting capital toward space-related names with higher explosive potential.

In the healthcare sector, ARK trimmed positions in both$Strata Critical Medical (SRTA.US)$ 26,006 shares and$CareDx (CDNA.US)$ 14,662 shares. Both moves likely reflect portfolio management adjustments: SRTA is involved in critical care equipment, while CDNA focuses on organ transplant monitoring. ARK may be reallocating capital toward more disruptive opportunities in precision medicine and gene editing.

The smallest sale came from$Brera Holdings (SLMT.US)$, with only 1,636 shares sold—a limited scale suggesting routine liquidity management or minor portfolio rebalancing.

Futubull’s [Opportunities Page] now features celebrity portfolio tracking! Choose from multiple celebrity holdings, follow top investors’ moves with one click, precisely target quality stocks, and invest with greater confidence!

111K Views